AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04530396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: vaccine for intramuscular injection
Study NCT04530396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT01752439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Study NCT01752439 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Study NCT03589820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: artificial liver support system
Description: Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
Study NCT00661102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: As prescribed
Study NCT00661102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As prescribed
Study NCT00661102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: As prescribed
Study NCT00661102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: As prescribed
Study NCT00661102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: As prescribed
Study NCT00661102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexpantenol [Bepantol]
Description: As prescribed
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tooth extraction
Description: Under local anesthesia, tooth will be extracted atraumatically.
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: Under local anesthesia, tooth will be extracted atraumatically.
Study NCT01365793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45% saline replacement fluid
Description: 10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
Study NCT01365793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline replacement fluid
Description: 10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
Study NCT05033574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
Study NCT01365793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45% saline intravenous fluid
Description: 0.45% saline fluid
Study NCT01365793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline Intravenous fluid
Description: 0.9% saline fluid
Study NCT03895294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care under the strategic purchase-Clinical pathway
Description: 1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Implant placement
Description: Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone augmentation
Description: Bone substitute will be used to augment or maintain the bone contour.
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation
Description: Bone substitute will be used to augment or maintain the bone contour.
Study NCT05033574 — intervention group
Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands
Study NCT04029324 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronally repositioned flap
Description: After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
Study NCT01962285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol targel controlled infusion
Description: slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
Study NCT00411086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
Study NCT00411086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
Study NCT05033574 — intervention group
Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
Study NCT03895294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care process prior strategic purchase-clinical pathway
Description: 1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
Study NCT00973401 — intervention group
Intervention type: OTHER
Intervention: Insulin pump
Description: Patients receive an insulin pump that optimizes their glucose control.
Study NCT02803229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR
Study NCT02803229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: matched placebo provided for placebo arm
Study NCT01904617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose
Study NCT01904617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study NCT03164785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinshuibao Capsule
Description: 1.98g t.i.d. p.o. for 6 months
Study NCT03384524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine 2.5 MG
Description: Administered daily
Study NCT03384524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 25 MG
Description: Administered daily
Study NCT03384524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.4 MG
Description: Administered daily
Study NCT00500747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCV E1E2/MF59
Description: The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
Study NCT00500747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
Study NCT03384524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three pills, matching active drugs to be administered daily
Study NCT01113996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein supplementation and strength training
Description: Protein supplementation and strength training
Study NCT01113996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Protein supplementation
Study NCT02238548 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14
Study NCT02238548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14
Study NCT02238548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw milk
Study NCT06397742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches
Study NCT06397742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy - myofascial techniques
Description: Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns.
Study NCT00830960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Oral, daily, 90 days
Study NCT03318276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID142
Description: SID142 is administrated to patients with PAD for 12 weeks
Study NCT03318276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinexin® Tab
Description: Rinexin® Tab is administrated to patients with PAD for 12 weeks
Study NCT01829841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib 25 mg p.o. qd
Study NCT01829841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib 50 mg p.o. qd
Study NCT00522171 — intervention group
Intervention type: DEVICE
Intervention: The Harmonic™ ultrasonic scalpel
Description: A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
Study NCT02262793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Study NCT02262793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan
Study NCT01798381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential fatty acids
Study NCT01798381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Essential fatty acids
Study NCT01971684 — intervention group
Intervention type: DRUG
Intervention: Second Line ITP agents
Description: The treating physicians will select the second line agent and clinical data will be collected.
Study NCT01789242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
Study NCT01789242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
Study NCT04624516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-structured foot exercise
Description: The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
Study NCT01730911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message
Description: Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
Study NCT03759236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messaging via SMS
Description: This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
Study NCT03759236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC Health Pamphlets
Description: This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
Study NCT00830960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral, daily, 90 days
Study NCT01223326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (NAC)
Description: NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
Study NCT02403297 — intervention group
Intervention type: DEVICE
Intervention: Quik Check PD
Description: The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
Study NCT02262793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA/ER-DP
Study NCT02262793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA/ER-DP
Study NCT04375683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib
Description: Flumatinib 600mg per day, taken on empty stomach
Study NCT02165865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper extremity/ hand transplantation
Description: hand transplant on unilateral dominant hand or bilateral upper extremity amputees
Study NCT04068636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.
Description: Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
Study NCT02839148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplementation
Description: Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS.
Study NCT01223326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Na Cl 0.9% infusion
Study NCT02746406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritron+
Description: Peritron+ device to measure intravesical pressure
Study NCT01272362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 µg once-daily via single-dose dry powder inhaler
Study NCT02398357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium and Warfarin
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
Study NCT00759902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate extended-release capsules
Description: 2 x 10 mg, single-dose capsule
Study NCT00759902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate extended-release) capsules
Description: 1 x 20 mg, single-dose capsule
Study NCT01087671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tafluprost
Description: prostaglandin analogue
Study NCT02493777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 methylphenidate hydrochloride (MPH) Capsules
Description: HLD200 doses: 20, 40, 60, 80 or 100 mg
Study NCT02493777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01943721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VISION5 Product
Study NCT04625595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
Study NCT04625595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
Study NCT04625595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
Study NCT04625595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Description: Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
Study NCT04244669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPG with Conventional Stimulation
Description: In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
Study NCT04244669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPG with SCS DTM
Description: In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
Study NCT04557202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Oral Capsule
Description: To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
Study NCT04557202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - control group
Study NCT03859037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord milking
Description: 100 babies will have squeezing of blood from umbilical cord towards baby
Study NCT03859037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: 100 babies will have squeezing of blood from umbilical cord towards baby
Study NCT01144143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: the study drug will be injected into the joint through a needle
Study NCT01144143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo will be injected into the joint through a needle
Study NCT01144143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: Methylprednisolone acetate
Description: Methylprednisolone acetate will be injected into the joint through a needle
Study NCT02458872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: safety huddle alarm intervention
Description: The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
Study NCT02879981 — intervention group
Intervention type: DRUG
Intervention: Guaifenesin
Description: Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.